ImmunityBio Secures Five US Patents for Anktiva, Extending Protection to 2035
IBRX has more than doubled off its 52-week low of $1.95.
Summary
ImmunityBio has announced the grant of five new U.S. patents for its key drug Anktiva (N-803) plus BCG in NMIBC. These patents provide intellectual property protection for treatment methods, dosing, formulations, and kits, extending through at least 2035. This is a significant positive development for the company, as it substantially strengthens the long-term competitive position and revenue potential of a critical product. The headline also references a "US Supply Deal," which appears to be a reiteration of the exclusive development and supply agreement with Japan BCG Laboratory that was previously announced via an 8-K and news on May 18th. While the supply deal is not new information, the patent wins are material and de-risk Anktiva's future, providing a strong catalyst for the stock.
At the time of this announcement, IBRX was trading at $8.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.4B. The 52-week trading range was $1.95 to $12.43. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.